Detalhe da pesquisa
1.
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
Blood;
139(14): 2145-2155, 2022 04 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34995344
2.
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.
Blood;
140(15): 1674-1685, 2022 10 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35960871
3.
Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase.
Haematologica;
109(4): 1082-1094, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37941406
4.
Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia.
Am J Hematol;
99(2): 182-192, 2024 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37782758
5.
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
Br J Haematol;
201(6): 1129-1143, 2023 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36990798
6.
Leveraging gene expression subgroups to classify DLBCL patients and select for clinical benefit from a novel agent.
Blood;
135(13): 1008-1018, 2020 03 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31977005
7.
Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.
Blood;
135(13): 996-1007, 2020 03 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31977002
8.
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study.
Blood;
134(17): 1395-1405, 2019 10 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31471376
9.
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Blood;
133(7): 676-687, 2019 02 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30510081
10.
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.
Am J Hematol;
98(4): E84-E87, 2023 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36655608
11.
A robust estimation of exon expression to identify alternative spliced genes applied to human tissues and cancer samples.
BMC Genomics;
15: 879, 2014 Oct 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25297679
12.
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
Leuk Res;
140: 107497, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38564986
13.
GATExplorer: genomic and transcriptomic explorer; mapping expression probes to gene loci, transcripts, exons and ncRNAs.
BMC Bioinformatics;
11: 221, 2010 Apr 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20429936
14.
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
Eur J Cancer;
108: 120-128, 2019 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30654297
15.
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.
J Clin Oncol;
34(25): 2988-96, 2016 09 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27354480
16.
ColoLipidGene: signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients.
Oncotarget;
6(9): 7348-63, 2015 Mar 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25749516
17.
TET2 overexpression in chronic lymphocytic leukemia is unrelated to the presence of TET2 variations.
Biomed Res Int;
2014: 814294, 2014.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24693539
18.
Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14.
PLoS One;
7(11): e48485, 2012.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23152777
19.
Human gene coexpression landscape: confident network derived from tissue transcriptomic profiles.
PLoS One;
3(12): e3911, 2008.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19081792